Tycel J. Phillips, MD

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma (MZL).

The CITADEL-204 trial has responses from the first 8 weeks, the AEs that occurred in result of the transition to maintenance therapy. Maintenance therapy was administered at 2.5 mg daily versus 20 mg weekly in this study. This dosing was chosen based on some of the other studies that evaluated this agent, according to Phillips. There was a difference in the maintenance dosing due to the response on the trial.

Phillips says that ultimately, the responses were great, the agent was well tolerated, and some of the information that the investigators believed was true, such as the 8-week response, came to fruition. These observations were the key takeaways from this research.

As more data are gathered, the next data that will be looked at are the mature responses, responses that are observed in different MZL subtypes, and the long-term toxicity data. Notably, the adverse events associated with PI3K inhibitors, in general, are one of the greatest roadblocks, according to Phillips. When comparing the data of parsaclisib with other approved agents in this setting, there were some similarities. Due to this, the investigators are hopeful that more agents will be approved in the future.

Videos

Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.

Phase 2 Trial of Parsaclisib Shows Efficacy in Marginal Zone Lymphoma

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses the current treatment options for patients with marginal zone lymphoma (MZL).

MZL is considered a low-grade lymphoma, says Phillips. For a long time, the only approved agent in the field for these patients was single-agent rituximab (Rituxan). The treatment approaches for patient with MZL also appear to piggy-back off those used for patients with follicular lymphoma.

Over the last 2 years, the field has seen a shift toward new advances. The Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) was granted approval for the treatment of patients with MZL, and the combination of lenalidomide (Revlimid) plus rituximab was approved for the treatment of patients with MZL who have been previously treated. These are now the only 2 agents approved for the treatment of these patients, says Phillips, but this is more so because it’s a smaller niche of patients that generally do well with most therapies.

Tycel J. Phillips, MD, discusses the current treatment options for patients with marginal zone lymphoma.

Reviewing Treatment Options for Patients With Marginal Zone Lymophoma

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib (Calquence) plus bendamustine and rituximab (Rituxan) in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL).

MCL is a rare subset of non-Hodgkin lymphoma and affects 5% to 6% of patients, Phillips says. It is common in patients over the age of 65, as well as in males. However, no official standard of care has been determined.

Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab&nbsp; in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.

Tycel J. Phillips, MD | Authors

Articles

Phase 2 Trial of Parsaclisib Shows Efficacy in Marginal Zone Lymphoma

Reviewing Treatment Options for Patients With Marginal Zone Lymophoma

Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL